Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging

Shanghai Mental Health Center300 enrolled

Overview

The purpose of this study is based on the Flutemetamol-PET senile plaque imaging to investigate the peripheral blood biochemical and brain MRI imaging biomarkers and to research completely independent intellectual property rights neuropsychological test tool for the MCI due to AD. At the same time, the investigators will study the efficacy and safety of early treatment of MCI due to AD by Huperzine A in 52 weeks.

This is a randmized, double-blind, placebo-controll study.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Enrollment

300

Conditions

Mild Cognitive Impairment Biomarker Diagnosis Treatment

Interventions

Huperzine ADRUG

The participants will treatment by the Huperzine A 200 ug/day in 52 weeks.

PlaceboDRUG

The participants will treatment by the placebo in 52 weeks.

Eligibility

Sex: ALLMin age: 55 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * memory complaint, preferably corroborated by a spouse or relative. * objective memory impairment. * normal general cognitive function. * intact activities of daily living. * absence of dementia. * the positive of brain senile plaque. Exclusion Criteria: * more than two lacuna ischemia (of diameter \< 1 cm) as revealed by MRI fluid-attenuated inversion recovery (FLAIR) sequence. * other type of dementia except AD

Locations (1)

Shanghai Mental Health Center

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

The average annual conversion rate in patients of MCI due to AD convert to the AD.

Time frame: 52 weeks

Central Contacts

Tao Wang, M.D., Ph.D.

CONTACT

00862164387250 wtshhwy@163.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.